NCT03126916

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

RecruitingPHASE3INTERVENTIONAL

Trial Details

Start: 2018-05-14Est. Completion: 2030-09-30

Enrollment target: 750 participants

Locations

Children's Hospital of Alabama, Birmingham, Alabama, United States
Phoenix Childrens Hospital, Phoenix, Arizona, United States
Arkansas Children's Hospital, Little Rock, Arkansas, United States
Kaiser Permanente Downey Medical Center, Downey, California, United States
Loma Linda University Medical Center, Loma Linda, California, United States
Children's Hospital Los Angeles, Los Angeles, California, United States
Mattel Children's Hospital UCLA, Los Angeles, California, United States
Valley Children's Hospital, Madera, California, United States
Kaiser Permanente-Oakland, Oakland, California, United States
Children's Hospital of Orange County, Orange, California, United States
Lucile Packard Children's Hospital Stanford University, Palo Alto, California, United States
University of California Davis Comprehensive Cancer Center, Sacramento, California, United States
Rady Children's Hospital - San Diego, San Diego, California, United States
Naval Medical Center -San Diego, San Diego, California, United States
UCSF Medical Center-Mission Bay, San Francisco, California, United States

Ganglioneuroblastoma, NodularNeuroblastoma

This phase III trial tests how well the addition of dinutuximab to Induction chemotherapy along with standard of care su…

Birmingham, United StatesEst. completion Dec 31, 2029

GanglioneuroblastomaHigh Risk Neuroblastoma

This phase II pilot trial studies the side effects and how well dinutuximab and sargramostim work when combined with che…

Los Angeles, United StatesCompleted Dec 31, 2021

MicrobiomeTrials does not provide medical advice. Always consult your doctor before joining a clinical trial.